Last reviewed · How we verify
Bupropion XL 300
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron.
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (as adjunctive therapy).
At a glance
| Generic name | Bupropion XL 300 |
|---|---|
| Also known as | Wellbutrin, Par, Mylan, Valeant |
| Sponsor | Washington University School of Medicine |
| Drug class | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
| Target | Norepinephrine transporter (NET), Dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the reuptake of norepinephrine and dopamine, bupropion increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling. Unlike SSRIs, it does not significantly affect serotonin reuptake. The XL formulation provides extended-release delivery for once-daily dosing, maintaining therapeutic levels throughout the day.
Approved indications
- Major depressive disorder
- Seasonal affective disorder
- Smoking cessation (as adjunctive therapy)
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Seizures
- Hypertension
Key clinical trials
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Relapse Prevention in Stimulant Use Disorder (EARLY_PHASE1)
- Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression (PHASE4)
- Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer (PHASE2)
- Smoking-Cessation and Stimulant Treatment (S-CAST) (PHASE3)
- Buproprion for Binge Drinking (PHASE2)
- Clinical Study of Generic and Brand Bupropion in Depression (PHASE4)
- An Open Label Trial of Bupropion and Naltrexone for Binge Drinking (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupropion XL 300 CI brief — competitive landscape report
- Bupropion XL 300 updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI